VistaGen Therapeutics, Inc.
VTGN
$2.22
-$0.12-5.13%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 698.30K | 875.30K | 970.30K | 1.06M | 1.04M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 698.30K | 875.30K | 970.30K | 1.06M | 1.04M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 698.30K | 875.30K | 970.30K | 1.06M | 1.04M |
| SG&A Expenses | 16.93M | 16.64M | 15.65M | 14.06M | 13.02M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 53.54M | 46.48M | 39.12M | 34.08M | 34.94M |
| Operating Income | -52.84M | -45.60M | -38.15M | -33.02M | -33.90M |
| Income Before Tax | -47.30M | -39.56M | -33.19M | -29.36M | -32.06M |
| Income Tax Expenses | 8.50K | 8.50K | 1.50K | 4.50K | 3.50K |
| Earnings from Continuing Operations | -47.30 | -39.57 | -33.19 | -29.36 | -32.07 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.30M | -39.57M | -33.19M | -29.36M | -32.07M |
| EBIT | -52.84M | -45.60M | -38.15M | -33.02M | -33.90M |
| EBITDA | -52.69M | -45.47M | -38.03M | -32.89M | -33.77M |
| EPS Basic | -1.54 | -1.30 | -1.53 | -2.12 | -3.52 |
| Normalized Basic EPS | -0.97 | -0.81 | -0.96 | -1.33 | -2.20 |
| EPS Diluted | -1.55 | -1.30 | -1.54 | -2.13 | -3.52 |
| Normalized Diluted EPS | -0.97 | -0.81 | -0.96 | -1.33 | -2.20 |
| Average Basic Shares Outstanding | 122.47M | 121.14M | 100.55M | 77.29M | 53.93M |
| Average Diluted Shares Outstanding | 122.47M | 121.14M | 100.55M | 77.29M | 53.93M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |